X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with IPCA Labs - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs IPCA LABS - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA IPCA LABS ASTRAZENECA PHARMA/
IPCA LABS
 
P/E (TTM) x 94.8 28.0 339.0% View Chart
P/BV x 13.5 2.1 629.7% View Chart
Dividend Yield % 0.0 0.2 -  

Financials

 ASTRAZENECA PHARMA   IPCA LABS
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
IPCA LABS
Mar-17
ASTRAZENECA PHARMA/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs1,285643 199.8%   
Low Rs634503 126.1%   
Sales per share (Unadj.) Rs189.6254.4 74.5%  
Earnings per share (Unadj.) Rs-0.216.1 -1.3%  
Cash flow per share (Unadj.) Rs3.829.8 12.9%  
Dividends per share (Unadj.) Rs01.00 0.0%  
Dividend yield (eoy) %00.2 0.0%  
Book value per share (Unadj.) Rs68.6194.6 35.3%  
Shares outstanding (eoy) m25.00126.20 19.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.12.3 224.7%   
Avg P/E ratio x-4,712.735.7 -13,219.0%  
P/CF ratio (eoy) x249.619.2 1,297.1%  
Price / Book Value ratio x14.02.9 474.7%  
Dividend payout %06.2 0.0%   
Avg Mkt Cap Rs m23,98872,300 33.2%   
No. of employees `0001.613.3 11.7%   
Total wages/salary Rs m1,6056,960 23.1%   
Avg. sales/employee Rs Th3,040.22,413.5 126.0%   
Avg. wages/employee Rs Th1,029.2523.2 196.7%   
Avg. net profit/employee Rs Th-3.3152.4 -2.1%   
INCOME DATA
Net Sales Rs m4,74032,106 14.8%  
Other income Rs m92226 40.8%   
Total revenues Rs m4,83232,332 14.9%   
Gross profit Rs m-1304,448 -2.9%  
Depreciation Rs m1011,730 5.9%   
Interest Rs m0241 0.0%   
Profit before tax Rs m-1392,703 -5.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1390-   
Tax Rs m5675 0.8%   
Profit after tax Rs m-52,028 -0.3%  
Gross profit margin %-2.713.9 -19.8%  
Effective tax rate %-3.725.0 -14.7%   
Net profit margin %-0.16.3 -1.7%  
BALANCE SHEET DATA
Current assets Rs m2,72617,340 15.7%   
Current liabilities Rs m2,4359,559 25.5%   
Net working cap to sales %6.124.2 25.4%  
Current ratio x1.11.8 61.7%  
Inventory Days Days74100 73.5%  
Debtors Days Days4157 71.7%  
Net fixed assets Rs m1,03520,779 5.0%   
Share capital Rs m50252 19.8%   
"Free" reserves Rs m94224,499 3.8%   
Net worth Rs m1,71624,553 7.0%   
Long term debt Rs m03,517 0.0%   
Total assets Rs m4,15639,595 10.5%  
Interest coverage xNM12.2-  
Debt to equity ratio x00.1 0.0%  
Sales to assets ratio x1.10.8 140.6%   
Return on assets %-0.15.7 -2.1%  
Return on equity %-0.38.3 -3.6%  
Return on capital %010.5 0.0%  
Exports to sales %5.748.6 11.7%   
Imports to sales %6.514.2 45.4%   
Exports (fob) Rs m27015,617 1.7%   
Imports (cif) Rs m3064,571 6.7%   
Fx inflow Rs m37515,617 2.4%   
Fx outflow Rs m4705,828 8.1%   
Net fx Rs m-969,790 -1.0%   
CASH FLOW
From Operations Rs m-82,764 -0.3%  
From Investments Rs m-146-1,432 10.2%  
From Financial Activity Rs m862-1,591 -54.2%  
Net Cashflow Rs m709-259 -273.8%  

Share Holding

Indian Promoters % 0.0 45.9 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 11.4 2.6%  
FIIs % 15.7 25.3 62.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 17.4 52.3%  
Shareholders   12,856 36,892 34.8%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   FULFORD INDIA  VENUS REMEDIES  STERLING BIOTECH  WOCKHARDT LTD.  AUROBINDO PHARMA  

Compare ASTRAZENECA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Flat Note; Coal India Stock Rallies 4.2%(Closing)

Indian share markets finished some selling pressure in the final hour of trade to finish flat amid weak European markets.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

Aug 4, 2017

The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Aug 17, 2017 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 8-QTR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS